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INTRODUCTION
Adverse pregnancy outcomes (APO) have recently been linked 
to inherited thrombophilias through extensive studies. How-
ever, conclusions regarding their association still remain incon-
sistent. Normal pregnancy is related with an acquired hyper-
coagulable state due to increased levels of coagulation factors, 
decreased levels of anticoagulants and decreased fibrinolytic 
activity.1 This hypercoagulability may be exacerbated in women 
with heritable predisposition to thrombosis, known as throm-
bophilia, and may contribute to various pregnancy complica-
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thrombin (AT), protein S (PS), and protein C (PC) deficiency, while the Novel group included methylentetrahydrofolate-reductase 
(MTHFR), plasminogen activator inhibitor-1 (PAI-1), and angiotensin converting enzyme (ACE) polymorphism. APO was defined 
as one of the following: preterm birth (PTB), fetal growth restriction (FGR), preeclampsia (PE), intrauterine fetal death (IUFD), pla-
cental abruption (PA) and deep venous thrombosis (DVT).
Results: There was no difference in distribution of births and spontaneous abortions between Conventional and Novel thrombophilia 
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ment reduced the incidence of IUFD (p=0.011) in Conventional and FGR, IUFD, and PTB in Novel thrombophilia group.
Conclusion: The equal impact of two thrombophilia types on the pregnancy outcomes and a more favorable effect of LMWH thera-
py on pregnancy complications in Novel thrombophilia group point the need for Novel thrombophilias screening and the future 
studies on this issue should be recommended.
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tions such as venous thromboembolism (VTE), deep venous 
thrombosis (DVT), first trimester abortion (FTA), mid-trimester 
abortion (MTA), intrauterine fetal death (IUFD), preeclamp-
sia (PE), placental abruption (PA), and fetal growth restriction 
(FGR).2-6 The most common types of inherited thrombophilias 
are the following: factor V Leiden (FVL) mutation, prothrombin 
G20210A (PT) mutation, deficiency of protein C (PC), deficien-
cy of protein S (PS) and the most thrombogenic, antithrombin 
(AT) deficiency. These conventional inherited thrombophilias 
can be identified in up to 50% of individuals with VTE, their im-
pact on APO has been well explored and they are included in 
the routine thrombophilia screening.7-10 The Novel inherited 
thrombophilias include methylentetrahydrofolate-reductase 
(MTHFR) gene C677T polymorphism,11-14 polymorphisms of 
plasminogen activator inhibitor-1 (PAI-1)15-18 and angiotensin 
converting enzyme (ACE)16,19,20 polymorphism. Although they 
are not rarely encountered, their impact on APO is still contro-
versial, available literature addressing this issue is limited and 
they are not routinely included in thrombophilia screening.
Due to available data indicating association between throm-
bophilias and APO, women with a history of pregnancy com-
plications and inherited thrombophilias are often offered an 
anticoagulant therapy with low molecular weight heparins 
(LMWH), since they are most common, because of its safety, 
easy administration and a very low incidence of complica-
tions.21-25
In the current study the primary objective was to evaluate 
the distribution of births and spontaneous abortions, FTA and 
MTA, in all untreated and in the last LMWH treated pregnan-
cies with regard to the Conventional and Novel thrombophilia 
types, in women with APO in previous untreated pregnancies. 
The secondary objective was to evaluate the impact of LMWH 
treatment in reducing the incidence of pregnancy complica-
tions in pregnancies ending in birth with regard to specific 
types of thrombophilia.
MATERIALS AND METHODS
This prospective cohort study included 50 women with any 
type of inherited thrombophilia and a history of APO and/or 
thromboembolic events in previous untreated pregnancies. 
The study was carried out between July 2008 and September 
2012. Participants were recruited at the Department of Obstet-
rics and Gynecology, University Hospital Split, Croatia, which 
serves as a tertiary referral hospital with approximately 4500 
deliveries per year. Institutional research and ethical approval 
was obtained before the commencement of the study (No. 003-
08/12-03/002) and all included participants have signed an in-
formed consent prior to the inclusion into the study.
APO in previous pregnancies was defined as: 1) three FTA 
(<12 weeks based on last menstrual period with previously 
proven fetal viability); 2) two FTA with at least one of the fol-
lowing pregnancy complications in their third pregnancy: (1) 
MTA defined as pregnancy loss between 12-21+6 weeks; (2) 
FGR defined by birth weight below the 5th percentile for ges-
tational age and gender according to the criteria adopted for 
the local population characteristics;26 (3) severe PE regardless 
of gestational age, defined as blood pressure >160/110 mm 
Hg, proteinuria >5 gr/24 hours; (4) HELLP syndrome in preg-
nancy or puerperium, defined by the presence of hemolysis, 
elevated serum aminotransferase concentrations and platelet 
count <100000 per cubic millimeter; (5) IUFD defined as fetal 
death ≥22 weeks; (6) PA; (7) preterm birth (PTB) defined as 
delivery before 37 weeks, and (8) thromboembolic event prior 
or during the pregnancy; 3) MTA; 4) IUFD; 5) pregnancy with 
some of the following complications: PE and/or HELLP, FGR, 
AP, and DVT (criteria are described above). Exclusion criteria 
were: 1) women older than 42 years; 2) presence of an ac-
quired thrombophilia; 3) congenital uterine anomaly; 4) peri-
natal infections (TORCH); 5) diabetes mellitus, endocrine ab-
normalities, chronic hypertension, renal impairment or drug 
abuse; 6) multiple pregnancy; 7) abnormal first-trimester 
screening test for fetal abnormalities; 8) abnormal karyotype; 
and 9) fetal malformations.
Having satisfied the inclusive criteria, their subsequent preg-
nancy was awaited and LMWH was administered. All women 
were advised to take periconceptional folic acid supplementa-
tion. The thromboprophylaxis was initiated between 5th and 
9th weeks of pregnancy, after proven fetal viability. Forty seven 
women were treated with dalteparin 2500 IU/day and three 
women, who started to receive therapy at another clinical cen-
ter, with enoxaparin 40 mg/day. Between 25th and 28th weeks 
of pregnancy, the dosage was doubled; dalteparin 5000 IU/
day and enoxaparin 80 mg/day. All women underwent regular 
antenatal examinations, including ultrasound and blood test-
ing to detect LMWH induced thrombocytopenia. LMWH was 
continued for 6 weeks postpartum.
Statistics
For the analysis of the quality variables, χ2 test and Fisher’s exact 
test were used. p≤0.05 was regarded as significant. The analyses 
were carried out using statistics package Statistics 10.0 (StaSoft, 
Tulsa, OK, USA).
RESULTS
In the cohort of 50 women, the FVL mutation (all heterozygous) 
was identified in 13 (26%), PT mutation (all heterozygous) in 
5 (10%), PC deficiency in 6 (12%), and PS deficiency in 6 (12%) 
women. MTHFR mutation (23 heterozygous and 2 homozy-
gous) was identified in 25 (50%), PAI-1 polymorphism in 33 
(66%) and ACE polymorphism in 25 (50%) women. Single mu-
tated gene was found in 7 (14%), two mutated genes in 25 (50%), 
three mutated genes in 16 (32%), and four mutated genes in 2 
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(4%) women. Based on the thrombophilia type, the patients 
were divided into two groups: Conventional thrombophilia 
group (comprising of women with conventional and combined 
thrombophilias) including 26 women (52%) and Novel throm-
bophilia group including 24 women (48%).
As shown in Table 1, analysis of the pregnancy outcomes with 
respect to the type of thrombophilia in untreated and LMWH 
treated pregnancies revealed no significant difference in dis-
tribution of births and spontaneous abortions (χ2=2.7; p=0.100), 
and even in the frequency of FTA and MTA (χ2=0.14; p=0.711) 
in untreated pregnancies (128 untreated pregnancies of the 
cohort of 50 women before the inclusion in the study). After 
inclusion into the study, the next pregnancy was treated with 
LMWH, and 48 out of the 50 treated pregnancies ended in 
birth and only 2 spontaneous abortions, suggesting significant 
improvement in pregnancy outcomes by the LMWH treatment. 
Moreover, in the LMWH treated pregnancies there was no dif-
ference in distribution of births and spontaneous abortions 
with respect to the thrombophilia type (χ2=0.442; p=0.506).
Analysis of specific pregnancy complications of pregnancies 
ending in birth in Conventional thrombophilia group (Table 2) 
revealed that LMWH treatment did not reduce the incidence of 
PTB (χ2=1.143; p=0.284), FGR (χ2=0.119; p=0.729), PE (χ2=1.988; 
p= 0.158), PA (p=0.682), and DVT (p=0.432). However, LMWH 
treatment significantly reduced the incidence of IUFD 
(p=0.011).
Analysis of the impact of LMWH treatment on specific com-
plications in pregnancies ending in birth in Novel thrombo-
philias group (Table 3) revealed that LMWH did not reduce 
the incidence of PE (χ2=0.016; p=0.899), PA (p=1.0), and DVT 
Table 1. Outcomes of Untreated and LMWH Treated Pregnancies Related to the Thrombophilia Type
 
Thrombophilia type
p value*
Conventional (n=26), n (%) Novel (n=24), n (%)
Total LMWH untreated pregnancies (n=128)
Births (n=48) 19 (15) 29 (23) 0.100
FTA+MTA (n=80) 45 (35) 35 (27)
FTA (n=66) 36 (45) 30 (38) 0.711
MTA (n=14)  9 (11) 5 (6)
LMWH treated pregnancies (n=50)
Births (n=48) 25 (50) 23 (46) 0.506
FTA and MTA (n=2) 1 (2) 1 (2)
LMWH, low molecular weight heparin; FTA, first-trimester abortion; MTA, mid-trimester abortion.
*χ2 test.
Table 2. The Impact of LMWH Treatment on Pregnancy Complications in Pregnancies Ending in Birth in Women with Conventional Thrombophilias
Outcome: BIRTH (n=48)
Pregnancy complications
Conventional thrombophilias
p value*†
No LMWH (n=19), n (%) LMWH (n=25), n (%)
Preterm birth 10 (52.6) 8 (32) 0.284*
Fetal growth restriction 8 (42.1) 13 (52) 0.729*
Preeclampsia 3 (15.7) 10 (40) 0.158*
Intrauterine fetal death 5 (26.31) 0 0.011†
Placental abruption 3 (15.7) 3 (12) 0.682†
Deep venous thrombosis 1 (5.26) 0 0.432†
LMWH, low molecular weight heparin.
*χ2 test, †Fisher’s exact test.
Table 3. The Impact of LMWH Treatment on Pregnancy Complications in Pregnancies Ending in Birth in Women with Novel Thrombophilias
Outcome: BIRTH (n=48)
Pregnancy complications 
Novel thrombophilias
p value*†
No LMWH (n=29), n (%) LMWH (n=23), n (%)
Preterm birth 12 (41.37) 3 (13.04) 0.053*
Intrauterine growth restriction 16 (55.17) 4 (17.39) 0.012*
Preeclampsia 7 (24.13) 5 (21.73) 0.899*
Intrauterine fetal death  9 (31.03) 0 0.003†
Placental abruption 1 (3.44) 0 1.0†
Deep venous thrombosis 1 (3.44) 1 (4.34) 1.0†
LMWH, low molecular weight heparin.
*χ2 test, †Fisher’s exact test.
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(p=1.0). However, LMWH decreased the frequency of PTB at 
95 % level of statistical significance (χ2=3.73; p=0.053). The 
LMWH treatment also resulted in 3.2 times decreased inci-
dence of FGR (χ2=6.221; p=0.012). Lastly, there was no cases of 
IUFD in the treated pregnancies as opposed to 9 cases in the 
untreated pregnancies (p=0.003). 
DISCUSSION
In the current study, we demonstrated that LMWH treatment 
significantly improved pregnancy outcomes and decreased 
the rate of spontaneous abortions irrespective of the type of 
thrombophilia. Moreover, analysis of the impact of LMWH 
treatment on the incidence of specific complications during 
pregnancies that ended in birth revealed that LMWH in Con-
ventional thrombophilia reduced only the incidence of IUFD, 
while LMWH treatment in Novel thrombophilias reduced the 
incidence of FGR, IUFD, and PTB.
Primary objective
In the present study, we found that the type of thrombophilias 
(Conventional vs. Novel) did not influence the distribution of 
births and spontaneous abortions in the overall number of 
untreated pregnancies (n=128). Moreover, the distribution of 
FTA and MTA did not differ with regard to the thrombophilia 
type. We also found that LMWH treatment significantly im-
proved the perinatal outcome (48 births and 2 spontaneous 
abortion), confirming our previous results.27 We compared two 
groups of thrombophilias in LMWH treated pregnancies (n=50) 
and found no difference in distribution of births and sponta-
neous abortions.
In the current study, therefore, we rather unexpectedly found 
that Conventional and Novel thrombophilias have equal ad-
verse impact on pregnancy outcome in women with APO in 
previous pregnancies. This is a rather novel finding, since there 
have been no studies on the analysis of the division of eight in-
herited thrombophilias into two groups. Also, a small number 
of similar studies presented conflicting results about the im-
pact of Novel thrombophilias on APO.11-20
The pathophysiological link between thrombophilias in gen-
eral and pregnancy complications was not unexpected. Pro-
cesses of impaired implantation caused by deficient tropho-
blast invasiveness during angiogenesis of the placental blood 
vessels, enhanced trophoblast apoptosis and coagulation in 
the intervillous space develop independently of the thrombo-
philia type. Therefore, various types of thrombophilia should 
develop the same pattern of the disease. However, it still re-
mains unexplained why some women with certain type of 
thrombophilia experience pregnancy complications, whereas 
the other women with the same thrombophilia type do not. 
Also, the reason remains unknown why the same woman may 
have regular and pathological pregnancies. There are two pos-
sible explanations for these questions: the existence of a still 
unidentified predisposition for development of disease that is 
only enhanced by the thrombophilias and co-existence of an 
additional, still unidentified thrombophilias (together with 
the known thrombophilias) that might enhance the impact of 
the existing ones. The fact that pregnancy complications occur 
earlier and more intensively in women with multiple thrombo-
philias supports the latter hypothesis.28
The equal distribution of FTA and MTA in both thrombophil-
ia types can be explained by the fact that the placentation oc-
curs in two phases, between the 8th and 12th and the 16th and 
18th week of the pregnancy, and that the thrombophilia type 
does not have an impact on the time of the occurrence of mis-
carriage. These results support the hypothesis that the etiogen-
esis of the pregnancy loss results from poor implantation and 
placentation, regardless of the duration of pregnancy.
Secondary objective
Analysis of the impact of LMWH treatment on pregnancy com-
plications in pregnancies ending in birth revealed that LMWH 
treatment in Conventional thrombophilias reduced the inci-
dence of IUFD only, whereas LMWH treatment in Novel throm-
bophilias reduced the incidence of FGR, IUFD, and PTB.
Our present findings of the lack of a favorable impact of 
LMWH on the incidence of PE and FGR in women with Con-
ventional thrombophilia are different from the results of pre-
vious small, non-randomized studies21-23 as well as one multi-
centre randomized controlled study (RCS) which demonstrated 
small, but statistically significant reduction of PE and FGR in 
LMWH treated pregnancies in women with inherited throm-
bophilia and history of APO.24 A possible explanation for such 
conflicting results might be found in different definitions of 
the pregnancy complications, different ethnical background 
and creation of an unrepresentative sample as a consequence. 
The small case control studies often include women with mild-
er forms and later onset of disease, consequently observing re-
duced incidence of PE and FGR in subsequent LMWH treated 
pregnancies.22,23 The principal strength of the only available 
RCS which demonstrated reduction of PE and FGR in LMWH 
treated pregnancies is the fact that the study examined only 
severe and early onset of PE and FGR.24
The results of previous studies on influence of LMWH treat-
ment on pregnancy complications in Novel thrombophilias are 
very sparse and conflicting. A limited number of studies showed 
an association of Novel thrombophilias with mostly PE13,19 and 
RPL,14-16,20 with conflicting conclusions. Furthermore, the last 
published study with the largest sample number of nullipa-
rous excluded the impact of PAI-1 polymorphism on APO.17 Fi-
nally, there is only a single study analysing the impact of LMWH 
in women with ACE polymorphism and concluded that it re-
duces the incidence of PE.25 Therefore, our present finding 
that LMWH treatment reduces the incidence of FGR, IUFD, 
and PTB in women with Novel thrombophilias constitutes 
http://dx.doi.org/10.3349/ymj.2016.57.5.12301234
Inherited Thrombophilia Types, Adverse Pregnancy Outcome
some novel data.
It should be emphasized that not a single case of IUFD was 
recorded in LMWH treated pregnancies regardless of the throm-
bophilia type: in untreated pregnancies, there were 5 cases of 
IUFD in Conventional group and even 9 cases of IUFD in Novel 
thrombophilia group. Improved outcome and reduced preg-
nancy complication may partially be due to intensive prenatal 
care in LMWH treated pregnancies.
The strengths of the current study include: 1) analysis of eight 
inherited thrombophilias in relation to APO; 2) thrombophilia 
division in two groups and its relation to APO; 3) very strict in-
clusive criteria; 4) clearly distinguished FTA and MTA; and 5) 
exclusion of women with acquired thrombophilia. The main 
limitations of the study are lack of control, untreated group of 
pregnant women and small sample size. The first limitation is 
common to all studies dealing with this topic, since it would be 
unethical to recruit participants and offer them placebo after 
devastating failures in previous pregnancies. The second limita-
tion is understandable, because of overall incidence of inherit-
ed thrombophilias and very strict inclusive criteria of the study.
In conclusion, our results suggest that distribution of births 
and spontaneous abortions is equal in Conventional and Nov-
el thrombophilia type in women with severe APO in previous 
pregnancies. Therefore, we recommend that the screening for 
thrombophilias should also include Novel thrombophilias in 
addition to Conventional thrombophilias. The study also sug-
gests that LMWH treatment is more effective in reducing APO 
in Novel thrombophilias. This is an additional reason why fu-
ture studies of Novel thrombophilias should be encouraged. 
Regardless of the limitations of the current study, we believe 
that the results emphasize the relevance of the topic of Novel 
thrombophilias in pregnancy and point the need for further re-
search.
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